228 related articles for article (PubMed ID: 32098624)
1. The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety.
Leonard CE; Brensinger CM; Dawwas GK; Deo R; Bilker WB; Soprano SE; Dhopeshwarkar N; Flory JH; Bloomgarden ZT; Gagne JJ; Aquilante CL; Kimmel SE; Hennessy S
Cardiovasc Diabetol; 2020 Feb; 19(1):25. PubMed ID: 32098624
[TBL] [Abstract][Full Text] [Related]
2. Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors and Sudden Cardiac Arrest and Ventricular Arrhythmia: Population-Based Cohort Studies.
Dawwas GK; Hennessy S; Brensinger CM; Deo R; Bilker WB; Soprano SE; Dhopeshwarkar N; Flory JH; Bloomgarden ZT; Aquilante CL; Kimmel SE; Leonard CE
Clin Pharmacol Ther; 2022 Jan; 111(1):227-242. PubMed ID: 34331322
[TBL] [Abstract][Full Text] [Related]
3. Risk of sudden cardiac arrest and ventricular arrhythmia with sulfonylureas: An experience with conceptual replication in two independent populations.
Dhopeshwarkar N; Brensinger CM; Bilker WB; Soprano SE; Flory JH; Dawwas GK; Gagne JJ; Hennessy S; Leonard CE
Sci Rep; 2020 Jun; 10(1):10070. PubMed ID: 32572080
[TBL] [Abstract][Full Text] [Related]
4. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
Ziyadeh N; McAfee AT; Koro C; Landon J; Arnold Chan K
Clin Ther; 2009 Nov; 31(11):2665-77. PubMed ID: 20110009
[TBL] [Abstract][Full Text] [Related]
5. Thiazolidinediones and reduced risk of incident bacterial abscess in adults with type 2 diabetes: A population-based cohort study.
Wang JL; Dong YH; Ko WC; Chang CH; Wu LC; Chuang LM; Chen PC
Diabetes Obes Metab; 2018 Dec; 20(12):2811-2820. PubMed ID: 29974616
[TBL] [Abstract][Full Text] [Related]
6. Comparative Safety of Sulfonylureas and the Risk of Sudden Cardiac Arrest and Ventricular Arrhythmia.
Leonard CE; Brensinger CM; Aquilante CL; Bilker WB; Boudreau DM; Deo R; Flory JH; Gagne JJ; Mangaali MJ; Hennessy S
Diabetes Care; 2018 Apr; 41(4):713-722. PubMed ID: 29437823
[TBL] [Abstract][Full Text] [Related]
7. Development of heart failure in Medicaid patients with type 2 diabetes treated with pioglitazone, rosiglitazone, or metformin.
Breunig IM; Shaya FT; McPherson ML; Snitker S
J Manag Care Spec Pharm; 2014 Sep; 20(9):895-903. PubMed ID: 25166288
[TBL] [Abstract][Full Text] [Related]
8. Comparative risk of serious hypoglycemia with oral antidiabetic monotherapy: A retrospective cohort study.
Leonard CE; Han X; Brensinger CM; Bilker WB; Cardillo S; Flory JH; Hennessy S
Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):9-18. PubMed ID: 29108130
[TBL] [Abstract][Full Text] [Related]
9. How Did Multiple FDA Actions Affect the Utilization and Reimbursed Costs of Thiazolidinediones in US Medicaid?
Hsu JC; Ross-Degnan D; Wagner AK; Zhang F; Lu CY
Clin Ther; 2015 Jul; 37(7):1420-1432.e1. PubMed ID: 25976425
[TBL] [Abstract][Full Text] [Related]
10. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events.
Starner CI; Schafer JA; Heaton AH; Gleason PP
J Manag Care Pharm; 2008; 14(6):523-31. PubMed ID: 18693776
[TBL] [Abstract][Full Text] [Related]
11. Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan.
Hsiao FY; Huang WF; Wen YW; Chen PF; Kuo KN; Tsai YW
Drug Saf; 2009; 32(8):675-90. PubMed ID: 19591532
[TBL] [Abstract][Full Text] [Related]
12. Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in Medicaid-enrolled patients with type 2 diabetes mellitus.
Balkrishnan R; Arondekar BV; Camacho FT; Shenolikar RA; Horblyuk R; Anderson RT
Clin Ther; 2007 Jun; 29(6 Pt 1):1306-15. PubMed ID: 18036392
[TBL] [Abstract][Full Text] [Related]
13. Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population.
Kalsekar I; Iyer S; Mody R; Rajagopalan R; Kavookjian J
J Manag Care Pharm; 2006 Mar; 12(2):121-9. PubMed ID: 16515370
[TBL] [Abstract][Full Text] [Related]
14. Hypoglycaemic episodes increase the risk of ventricular arrhythmia and sudden cardiac arrest in patients with type 2 diabetes-A nationwide cohort study.
Hsieh YC; Liao YC; Li CH; Lin JC; Weng CJ; Lin CC; Lo CP; Huang KC; Huang JL; Lin CH; Wang JS; Wu TJ; Sheu WH
Diabetes Metab Res Rev; 2020 Feb; 36(2):e3226. PubMed ID: 31655001
[TBL] [Abstract][Full Text] [Related]
15. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.
Mamtani R; Haynes K; Bilker WB; Vaughn DJ; Strom BL; Glanz K; Lewis JD
J Natl Cancer Inst; 2012 Sep; 104(18):1411-21. PubMed ID: 22878886
[TBL] [Abstract][Full Text] [Related]
16. Association between extent of thiazolidinedione exposure and risk of acute myocardial infarction.
Dore DD; Trivedi AN; Mor V; Lapane KL
Pharmacotherapy; 2009 Jul; 29(7):775-83. PubMed ID: 19558251
[TBL] [Abstract][Full Text] [Related]
17. Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US.
Tunis SL; Minshall ME; St Charles M; Pandya BJ; Baran RW
Curr Med Res Opin; 2008 Nov; 24(11):3085-96. PubMed ID: 18826750
[TBL] [Abstract][Full Text] [Related]
18. Thiazolidinediones, cardiovascular disease and cardiovascular mortality: translating research into action for diabetes (TRIAD).
Bilik D; McEwen LN; Brown MB; Selby JV; Karter AJ; Marrero DG; Hsiao VC; Tseng CW; Mangione CM; Lasser NL; Crosson JC; Herman WH
Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):715-21. PubMed ID: 20583206
[TBL] [Abstract][Full Text] [Related]
19. Pioglitazone and PPAR-γ modulating treatment in hypertensive and type 2 diabetic patients after ischemic stroke: a national cohort study.
Liu CH; Lee TH; Lin YS; Sung PS; Wei YC; Li YR
Cardiovasc Diabetol; 2020 Jan; 19(1):2. PubMed ID: 31910836
[TBL] [Abstract][Full Text] [Related]
20. Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in medicaid-enrolled patients with type 2 diabetes mellitus.
Balkrishnan R; Arondekar BV; Camacho FT; Shenolikar RA; Horblyuk R; Anderson RT
Clin Ther; 2007; 29 Spec No():1306-15. PubMed ID: 18046930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
